Nifty
Sensex
:
:
17843.15
60614.72
121.65 (0.69%)
328.68 (0.55%)

Pharmaceuticals & Drugs - API

Rating :
48/99

BSE: 524558 | NSE: NEULANDLAB

1445.20
08-Feb-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 1430.20
  • 1461.60
  • 1412.65
  • 1416.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  11561
  •  166.33
  •  2002.00
  •  967.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,854.11
  • 21.96
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,064.70
  • 0.35%
  • 2.07

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.14%
  • 5.65%
  • 30.09%
  • FII
  • DII
  • Others
  • 17.7%
  • 1.25%
  • 9.17%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.52
  • 12.52
  • 7.63

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.48
  • 23.11
  • 6.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.50
  • 39.55
  • 57.90

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.70
  • 35.19
  • 29.07

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.90
  • 2.12
  • 2.17

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.35
  • 14.27
  • 13.09

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
293.71
257.85
13.91%
221.17
200.89
10.10%
255.87
244.71
4.56%
236.47
245.39
-3.64%
Expenses
224.41
215.01
4.37%
192.57
175.20
9.91%
217.00
219.19
-1.00%
204.04
198.79
2.64%
EBITDA
69.30
42.83
61.80%
28.60
25.69
11.33%
38.87
25.51
52.37%
32.43
46.60
-30.41%
EBIDTM
23.59%
16.61%
12.93%
12.79%
15.19%
10.43%
13.72%
18.99%
Other Income
0.24
0.29
-17.24%
0.51
2.06
-75.24%
0.63
14.60
-95.68%
1.90
0.20
850.00%
Interest
3.17
3.56
-10.96%
2.86
3.84
-25.52%
2.77
4.58
-39.52%
3.32
4.44
-25.23%
Depreciation
13.17
11.98
9.93%
12.80
11.83
8.20%
12.45
11.14
11.76%
12.78
10.41
22.77%
PBT
53.19
27.58
92.86%
13.46
12.07
11.52%
24.28
24.39
-0.45%
18.24
31.95
-42.91%
Tax
14.73
7.21
104.30%
3.49
3.34
4.49%
2.50
7.10
-64.79%
5.30
5.21
1.73%
PAT
38.46
20.37
88.81%
9.97
8.73
14.20%
21.78
17.29
25.97%
12.94
26.74
-51.61%
PATM
13.10%
7.90%
4.51%
4.35%
8.51%
7.07%
5.47%
10.90%
EPS
29.81
15.79
88.79%
7.73
6.77
14.18%
16.88
13.41
25.88%
10.03
20.72
-51.59%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
1,007.22
951.08
936.91
762.71
666.83
527.41
578.89
509.97
469.15
465.69
460.59
Net Sales Growth
6.15%
1.51%
22.84%
14.38%
26.43%
-8.89%
13.51%
8.70%
0.74%
1.11%
 
Cost Of Goods Sold
423.16
422.14
438.42
380.20
366.24
238.37
262.90
253.46
243.99
246.53
269.20
Gross Profit
584.06
528.94
498.50
382.51
300.59
289.04
315.99
256.52
225.16
219.16
191.39
GP Margin
57.99%
55.61%
53.21%
50.15%
45.08%
54.80%
54.59%
50.30%
47.99%
47.06%
41.55%
Total Expenditure
838.02
808.46
790.09
660.82
608.46
476.98
472.55
429.52
402.53
395.08
402.91
Power & Fuel Cost
-
42.21
39.21
32.75
26.81
25.95
25.78
22.24
22.53
18.31
18.97
% Of Sales
-
4.44%
4.19%
4.29%
4.02%
4.92%
4.45%
4.36%
4.80%
3.93%
4.12%
Employee Cost
-
182.47
149.74
123.56
110.46
102.99
92.74
65.38
51.81
41.74
40.75
% Of Sales
-
19.19%
15.98%
16.20%
16.56%
19.53%
16.02%
12.82%
11.04%
8.96%
8.85%
Manufacturing Exp.
-
89.16
77.10
64.84
50.10
55.54
44.90
39.31
43.56
40.98
35.86
% Of Sales
-
9.37%
8.23%
8.50%
7.51%
10.53%
7.76%
7.71%
9.28%
8.80%
7.79%
General & Admin Exp.
-
35.80
38.93
27.75
27.49
33.32
28.30
29.72
23.59
15.95
16.27
% Of Sales
-
3.76%
4.16%
3.64%
4.12%
6.32%
4.89%
5.83%
5.03%
3.43%
3.53%
Selling & Distn. Exp.
-
27.40
34.63
18.30
18.28
14.04
11.16
17.52
14.54
26.57
13.51
% Of Sales
-
2.88%
3.70%
2.40%
2.74%
2.66%
1.93%
3.44%
3.10%
5.71%
2.93%
Miscellaneous Exp.
-
9.28
12.08
13.42
9.08
6.77
6.78
1.89
2.52
4.99
13.51
% Of Sales
-
0.98%
1.29%
1.76%
1.36%
1.28%
1.17%
0.37%
0.54%
1.07%
1.81%
EBITDA
169.20
142.62
146.82
101.89
58.37
50.43
106.34
80.45
66.62
70.61
57.68
EBITDA Margin
16.80%
15.00%
15.67%
13.36%
8.75%
9.56%
18.37%
15.78%
14.20%
15.16%
12.52%
Other Income
3.28
2.08
16.10
3.89
3.49
4.53
1.17
1.78
0.78
3.44
4.06
Interest
12.12
13.50
17.90
21.57
15.66
18.93
21.09
24.48
27.36
24.56
31.33
Depreciation
51.20
49.04
39.68
31.28
25.86
22.10
19.23
15.74
15.32
14.94
14.62
PBT
109.17
82.16
105.33
52.92
20.34
13.93
67.19
42.00
24.72
34.55
15.78
Tax
26.02
18.34
24.70
36.71
3.90
1.87
20.32
14.92
8.79
7.80
1.96
Tax Rate
23.83%
22.32%
23.45%
69.37%
19.17%
13.42%
30.24%
35.52%
35.56%
22.58%
12.42%
PAT
83.15
63.82
80.63
16.21
16.44
12.06
46.86
27.33
15.94
26.80
13.86
PAT before Minority Interest
83.15
63.82
80.63
16.21
16.44
12.06
46.86
27.08
15.93
26.75
13.82
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.25
0.01
0.05
0.04
PAT Margin
8.26%
6.71%
8.61%
2.13%
2.47%
2.29%
8.09%
5.36%
3.40%
5.75%
3.01%
PAT Growth
13.70%
-20.85%
397.41%
-1.40%
36.32%
-74.26%
71.46%
71.46%
-40.52%
93.36%
 
EPS
64.96
49.86
62.99
12.66
12.84
9.42
36.61
21.35
12.45
20.94
10.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
840.50
786.46
709.96
699.31
558.04
545.62
186.63
161.38
123.99
99.83
Share Capital
12.90
12.90
12.90
12.90
8.95
8.95
8.95
8.95
7.73
7.72
Total Reserves
827.60
773.56
697.06
686.41
238.24
225.81
177.68
152.42
116.26
92.12
Non-Current Liabilities
179.83
169.82
163.39
104.06
146.43
54.37
69.42
54.76
52.33
61.85
Secured Loans
104.25
88.13
77.37
60.72
103.49
29.81
33.40
21.22
8.87
26.11
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
12.00
12.00
25.00
25.00
Long Term Provisions
11.91
9.44
12.49
11.91
9.87
9.28
6.85
6.38
5.14
4.71
Current Liabilities
363.16
368.51
357.63
326.98
366.93
285.60
268.00
295.14
306.90
262.99
Trade Payables
112.27
152.13
115.56
119.68
124.29
85.92
83.86
111.81
93.94
82.02
Other Current Liabilities
157.46
158.75
71.63
57.45
41.83
47.18
55.02
31.28
63.74
40.46
Short Term Borrowings
92.21
56.98
168.17
149.06
199.20
151.08
123.63
145.80
139.62
132.68
Short Term Provisions
1.21
0.64
2.27
0.80
1.59
1.41
5.50
6.25
9.61
7.83
Total Liabilities
1,383.49
1,324.79
1,230.98
1,130.35
1,071.40
885.59
524.05
511.53
483.48
424.98
Net Block
747.70
696.94
622.76
511.69
445.01
435.74
138.77
123.07
130.85
135.52
Gross Block
919.62
826.48
714.33
575.44
483.45
454.74
291.78
263.65
258.54
250.39
Accumulated Depreciation
171.92
129.54
91.57
63.75
38.44
19.00
153.00
140.58
127.69
114.87
Non Current Assets
800.71
775.20
715.79
676.88
624.20
510.54
209.87
195.76
195.93
197.66
Capital Work in Progress
20.46
17.25
23.75
104.47
126.09
19.60
40.48
41.47
34.56
35.69
Non Current Investment
20.16
19.35
30.17
30.21
30.21
30.20
7.39
7.39
7.36
7.36
Long Term Loans & Adv.
12.40
41.67
35.81
30.51
22.66
24.79
22.73
23.83
23.15
10.99
Other Non Current Assets
0.00
0.00
3.30
0.00
0.22
0.22
0.50
0.00
0.00
8.09
Current Assets
582.78
549.59
515.19
453.47
447.19
375.04
314.19
315.77
287.55
227.32
Current Investments
3.38
6.46
7.50
7.50
7.50
7.50
0.00
0.00
0.00
0.00
Inventories
265.21
247.61
219.55
192.65
175.09
135.11
126.66
113.40
93.42
92.17
Sundry Debtors
234.33
217.73
189.89
164.02
193.92
181.11
119.11
128.85
118.59
98.50
Cash & Bank
20.36
19.40
46.98
37.84
17.26
12.49
9.71
6.98
7.07
1.18
Other Current Assets
59.50
8.84
17.47
19.69
53.43
38.83
58.70
66.53
68.47
35.48
Short Term Loans & Adv.
47.98
49.55
33.80
31.77
37.15
25.30
46.68
45.23
43.01
25.66
Net Current Assets
219.62
181.08
157.55
126.49
80.27
89.45
46.18
20.63
-19.35
-35.66
Total Assets
1,383.49
1,324.79
1,230.98
1,130.35
1,071.39
885.58
524.06
511.53
483.48
424.98

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
58.58
189.36
57.34
69.91
11.27
38.68
44.83
13.17
48.77
25.83
PBT
82.16
105.33
52.92
20.34
13.93
67.19
42.00
24.72
34.55
15.78
Adjustment
64.50
40.08
58.28
39.11
40.43
43.96
33.73
36.34
34.37
42.22
Changes in Working Capital
-67.58
49.22
-49.17
15.47
-40.02
-55.94
-19.17
-38.76
-16.82
-31.35
Cash after chg. in Working capital
79.07
194.63
62.03
74.91
14.35
55.20
56.56
22.30
52.11
26.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-20.49
-5.27
-4.68
-5.01
-3.08
-16.52
-11.73
-9.13
-3.34
-0.82
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-93.71
-84.42
-48.68
-77.23
-116.29
-42.11
-19.86
-14.13
-9.84
-7.22
Net Fixed Assets
-96.36
-105.64
-58.17
-70.35
-135.20
-142.08
-27.14
-12.02
-7.02
-4.86
Net Investments
2.27
11.87
0.04
0.00
-0.01
-30.31
0.12
-0.03
0.00
0.03
Others
0.38
9.35
9.45
-6.88
18.92
130.28
7.16
-2.08
-2.82
-2.39
Cash from Financing Activity
37.72
-113.66
-5.48
11.98
104.85
-0.09
-23.62
1.15
-38.96
-19.90
Net Cash Inflow / Outflow
2.59
-8.72
3.18
4.66
-0.17
-3.51
1.35
0.19
-0.03
-1.28
Opening Cash & Equivalents
2.44
11.20
7.94
3.29
3.44
6.97
0.81
0.62
0.65
1.93
Closing Cash & Equivalent
5.09
2.44
11.20
7.94
3.29
3.44
2.16
0.81
0.62
0.65

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
654.40
612.28
552.65
544.35
277.21
263.23
209.07
180.72
153.48
123.40
ROA
4.71%
6.31%
1.37%
1.49%
1.23%
6.65%
5.23%
3.20%
5.89%
3.26%
ROE
7.85%
10.79%
2.30%
3.48%
5.02%
22.34%
15.64%
11.24%
24.14%
15.92%
ROCE
9.44%
12.81%
7.85%
3.99%
4.07%
15.98%
18.57%
15.75%
18.99%
15.58%
Fixed Asset Turnover
1.09
1.22
1.18
1.26
1.13
1.57
1.86
1.82
1.87
1.86
Receivable days
86.74
79.40
84.68
97.96
129.34
93.22
87.45
94.81
83.45
75.67
Inventory Days
98.40
91.00
98.63
100.64
106.98
81.29
84.66
79.24
71.34
71.66
Payable days
114.31
111.44
65.43
75.72
82.06
67.03
85.01
92.70
82.14
88.22
Cash Conversion Cycle
70.84
58.96
117.88
122.89
154.27
107.48
87.10
81.35
72.66
59.11
Total Debt/Equity
0.28
0.22
0.37
0.33
1.30
0.82
0.98
1.17
1.55
2.13
Interest Cover
7.09
6.89
3.45
2.30
1.74
4.19
2.72
1.90
2.41
1.50

News Update:


  • Neuland Laboratories gets nod to transfer Telangana property to various parties
    24th Nov 2022, 11:59 AM

    The Board of Directors at their meeting held on November 23, 2022, has approved the same

    Read More
  • Neuland Laboratories - Quarterly Results
    10th Nov 2022, 18:15 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.